Tricida, Inc.
Tricida, Inc. (TCDA): 1 pipeline candidate · ~12 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.4 months
D/E -1.69 · 4% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Tricida, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$17.7M
Quarterly Burn
$18.7M
Runway
12.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| veverimer | Phase 3 |
Frequently asked questions
How many drug candidates are in Tricida, Inc.'s pipeline?
Tricida, Inc. (TCDA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tricida, Inc.'s lead drug candidate?
Tricida, Inc.'s most advanced tracked candidate is veverimer (Phase 3) for metabolic acidosis in patients with chronic kidney disease (CKD).
What is Tricida, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tricida, Inc. has approximately 12.4 months of cash runway.
Get the full picture on Tricida, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.